Cataract TherapeuticsGlaucoma InsightsBranded vs GenericsCME ActivitiesGlaucoma Management

CataractClinical DiagnosisCorneaGlaucomaIOLOCTOcular AllergyOcular Surface DiseasePediatricsRefractiveRetinaTechnologyTherapeutic Cataract & RefractiveUnderstanding Antibiotic Resistance

All NewsBlogsCOVID-19

Expert InterviewsMedical World NewsPodcastsViewpoints

Health Law & PolicyMoney MattersPersonal FinancePractice Management

Conference CoverageConference Listing

Digital EditionEurope Ophthalmology TimesModern Retina

CMEJob BoardSponsored Resources

eNewsletterPrint Subscription

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences and Ophthalmology Times. All rights reserved.

Spotlight

Cataract Therapeutics
Glaucoma Insights
Branded vs Generics
CME Activities
Glaucoma Management

ClinicalSee All >

Cataract
Clinical Diagnosis
Cornea
Glaucoma
IOL
OCT
Ocular Allergy
Ocular Surface Disease
Pediatrics
Refractive
Retina
Technology
Therapeutic Cataract & Refractive
Understanding Antibiotic Resistance

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2020 MJH Life Sciences^™ and Ophthalmology Times. All rights reserved.

Injection application accepted by FDA

December 15, 2003

The FDA is weighing the application by Amphastar Pharmaceuticals Inc. for a hyaluronidase injection 150 units/ml, 1ml.